Aarhus University Seal / Aarhus Universitets segl

Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

  • Fabio Colella, University of Aberdeen
  • ,
  • João Pedro Garcia, Utrecht University
  • ,
  • Marco Sorbona, Imperial College London
  • ,
  • Andrea Lolli, Erasmus University Rotterdam
  • ,
  • Bernardo Antunes, Hebrew University of Jerusalem, Procore Ltd.
  • ,
  • Domenico D'Atri, Technion-Israel Institute of Technology
  • ,
  • Florian P.Y. Barré, Maastricht University
  • ,
  • Jacopo Oieni, Technion-Israel Institute of Technology
  • ,
  • Maria Letizia Vainieri, Erasmus University Rotterdam, AO Research Institute
  • ,
  • Luana Zerrillo, Leiden University
  • ,
  • Serdar Capar, Erasmus University Rotterdam
  • ,
  • Sonja Häckel, AO Research Institute, University of Bern
  • ,
  • Yunpeng Cai
  • ,
  • Laura B. Creemers, Utrecht University

Osteoarthritis (OA) and intervertebral disc degeneration (IVDD) as major cause of chronic low back pain represent the most common degenerative joint pathologies and are leading causes of pain and disability in adults. Articular cartilage (AC) and intervertebral discs are cartilaginous tissues with a similar biochemical composition and pathophysiological aspects of degeneration. Although treatments directed at reversing these conditions are yet to be developed, many promising disease-modifying drug candidates are currently under investigation. Given the localized nature of these chronic diseases, drug delivery systems have the potential to enhance therapeutic outcomes by providing controlled and targeted release of bioactives, minimizing the number of injections needed and increasing drug concentration in the affected areas. This review provides a comprehensive overview of the currently most promising disease-modifying drugs as well as potential drug delivery systems for OA and IVDD therapy.

TidsskriftJournal of Controlled Release
Sider (fra-til)985-999
Antal sider15
StatusUdgivet - dec. 2020

Bibliografisk note

Funding Information:
This work was supported by European Union's Horizon 2020 Research And Innovation Programme under Marie Sklodowska Curie Grant agreement no. 642414 .

Publisher Copyright:
© 2020 The Authors

Copyright 2021 Elsevier B.V., All rights reserved.

Se relationer på Aarhus Universitet Citationsformater

ID: 217269226